Sanofi SA
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878
Sanofi SA News & Analysis
stocks
10 best US blue-chip stocks to buy for the long term
personal-finance
Can you achieve global diversification with multinational companies?
stocks
Magnificent Seven vs. the ‘Granolas’: How does Europe’s version stack up?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,001.40 | 59.90 | 0.67% |
CAC 40 | 7,850.43 | 106.02 | 1.37% |
DAX 40 | 24,240.82 | 198.92 | 0.83% |
Dow JONES (US) | 44,872.39 | 369.95 | 0.83% |
FTSE 100 | 9,061.49 | 37.68 | 0.42% |
HKSE | 25,538.07 | 408.04 | 1.62% |
NASDAQ | 20,938.29 | 45.60 | 0.22% |
Nikkei 225 | 41,171.32 | 1,396.40 | 3.51% |
NZX 50 Index | 12,794.06 | 39.68 | -0.31% |
S&P 500 | 6,339.34 | 29.72 | 0.47% |
S&P/ASX 200 | 8,737.20 | 60.00 | 0.69% |
SSE Composite Index | 3,582.30 | 0.44 | 0.01% |